State Government Officials\u27 Role in U.S./Mexico Transboundary Resource Issues

Analyses state roles in foreign policy by examining the broader picture of policymaking concerning US/Mexico transboundary resource issues and what roles states have to play in the policymaking process. Observers of natural resources issues on the US/Mexico border have been warning for some time that the seriousness of problems concerning such issues is escalating. Institutional and political capacity to deal successfully with these problems has not kept pace. This paper examines the nature of these issues, the incentives for and factors influencing the negotiation of binational settlements, and the role of state decisionmakers in that negotiation process. It also takes a closer look at the domestic US policymaking process concerning transboundary resource issues and examines state government officials' roles at the different stages of the process from initial agenda setting to implementation. Specific examples from case studies are cited and shortcomings of the existing decision processes are summarized. -from Autho

Antibiotic Therapy and the Gut Microbiome:Investigating the Effect of Delivery Route on Gut Pathogens

The contribution of the gut microbiome to human health has long been established, with normal gut microbiota conferring protection against invasive pathogens. Antibiotics can disrupt the microbial balance of the gut, resulting in disease and the development of antimicrobial resistance. The effect of antibiotic administration route on gut dysbiosis remains under-studied to date, with conflicting evidence on the differential effects of oral and parenteral delivery. We have profiled the rat gut microbiome following treatment with commonly prescribed antibiotics (amoxicillin and levofloxacin), via either oral or intravenous administration. Fecal pellets were collected over a 13-day period and bacterial populations were analyzed by 16S rRNA gene sequencing. Significant dysbiosis was observed in all treatment groups, regardless of administration route. More profound dysbiotic effects were observed following amoxicillin treatment than those with levofloxacin, with population richness and diversity significantly reduced, regardless of delivery route. The effect on specific taxonomic groups was assessed, revealing significant disruption following treatment with both antibiotics. Enrichment of a number of groups containing known gut pathogens was observed, in particular, with amoxicillin, such as the family Enterobacteriaceae. Depletion of other commensal groups was also observed. The degree of dysbiosis was significantly reduced toward the end of the sampling period, as bacterial populations began to return to pretreatment composition. Richness and diversity levels appeared to return to pretreatment levels more quickly in intravenous groups, suggesting convenient parenteral delivery systems may have a role to play in reducing longer term gut dysbiosis in the treatment of infection

Synthesis and Assessment Product

This Synthesis and Assessment Product focuses on the connection between the scientific ability to predict climate on seasonal scales and the opportunity to incorporate such understanding into water resource management decisions. It directly addresses decision support experiments and evaluations that have used seasonal-to-interannual forecasts and observational data, and is expected to inform (1) decision makers about the relative success of experiences of others who have experimented with these forecasts and data in resource management; (2) climatologists, hydrologists, and social scientists on how to advance the delivery of decision-support resources that use the most recent forecast products, methodologies, and tools; and (3) science and resource managers as they plan for future investments in research related to forecasts and their role in decision support. It is important to note, however, that while the focus of this Product is on the water resources management sector, the findings within this Synthesis and Assessment Product may be directly transferred to other sectors

Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS) : protocol for a prospective cohort study

Background: Hidradenitis suppurativa (HS) is a chronic, painful, inflammatory skin disease with estimates of prevalence in the European population of 1%–2%. Despite being a relatively common condition, the evidence base for management of HS is limited. European and North American management guidelines rely on consensus for many aspects of treatment and within the UK variations in management of HS have been identified. The HS James Lind Alliance Priority Setting Partnership (PSP) published a top 10 list of future HS research priorities including both medical and surgical interventions. The aims of the THESEUS study are to inform the design of future HS randomised controlled trials (RCTs) and to understand how HS treatments are currently used. THESEUS incorporates several HS PSP research priorities, including investigation of oral and surgical treatments. Core outcome domains have been established by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) and THESEUS is designed to validate instruments to measure the domains. Methods and analysis: The THESEUS study is a prospective observational cohort study. Participants, adults with active HS of any severity, will be asked to select one of five HS treatment options that is appropriate for their HS care. Participants will be allocated to their chosen treatment intervention and followed for a period of up to 12 months. Outcomes will be assessed at 3-monthly intervals using HISTORIC core outcome instruments. Video recordings of the surgical and laser operations will provide informational and training videos for future trials. Nested mixed-methods studies will characterise the interventions in clinical practice, understand facilitators and barriers to recruitment into future HS RCTs and examine patients’ and clinicians’ perspectives on HS treatment choices. Trial registration number: ISRCTN69985145